PT 639 - Evelyn Eddy Shoop PMHNP-BC: Lived Experience, Qualitative Data, and the Future of Psychedelic Care

Overview

Evelyn Eddy Shoop PMHNP-BC joins Psychedelics Today to share her journey from Division I athlete to psychiatric mental health nurse practitioner and psilocybin research participant. In this conversation, she explains how sports injuries, OCD, and intensive treatment led her into psychiatry and eventually into a psilocybin clinical trial at Yale. Her story weaves together lived experience, clinical training, and a call for more humane systems of care and better qualitative data in psychedelic science.

Early Themes: Injury, OCD, and Choosing Psychiatry

Early in the episode, Evelyn Eddy Shoop PMHNP-BC describes how multiple season ending injuries in college and serious mental health stressors in her family pushed her to rethink her life path. Originally pre vet, she stepped away from veterinary medicine after realizing she could not tolerate that environment.

During a semester off for surgery and mental health, she completed intensive outpatient treatment and family therapy. That time showed her how powerful psychological work could be. It also reawakened a long standing curiosity about the brain, consciousness, and human experience. This led her to switch her major to psychology and later pursue psychiatric mental health nurse practitioner training at the University of Pennsylvania.

At Penn, she felt supported academically and personally. Her interest in psychedelics grew as she realized that standard OCD treatments and high dose SSRIs were not giving her the level of functioning or happiness she knew was possible.

Core Insights: Psilocybin Trials, Qualitative Data, and Clinical Skepticism

In the middle of the episode, Eddy shares the story of finding a psilocybin trial on ClinicalTrials.gov just as she was about to start ketamine therapy. She received placebo first, then open label psilocybin, and describes the dosing day as one of the hardest days of her life, with benefits that emerged slowly over months through integration.

She uses her experience to highlight why qualitative data matters. Numbers alone cannot capture the depth of a psychedelic journey or the slow unfolding of meaning over time. She argues that subjective stories, even difficult ones, are essential for clinicians, researchers, and policymakers.

Key themes include:

• The central role of integration support in turning a crisis level session into lasting growth
• How trial environments on inpatient psychiatric units can feel like prison instead of healing spaces
• The limits of double blind placebo trials when participants become desperate for active treatment
• The need for more nuanced language around psychosis and psychedelic harms

Eddy also addresses skepticism in psychiatry. Many providers fear substance induced psychosis and feel uneasy with medicines whose mechanisms are not fully understood. She suggests that more lived experience stories and careful education can help bridge that gap.

Later Discussion and Takeaways

In the later part of the episode, Eddy and Joe discuss harm reduction, ketamine risks, and how poorly designed systems can create harm even when the medicine itself is helpful. Eddy describes being treated as "just another psych patient" once the research team left for the day, including being denied basic comforts like headache relief after an emotionally intense session.

She calls for:

• More humane hospital and research environments
• Required psychedelic education in psychiatric training
• Honest, nonjudgmental conversations about substance use with patients
• Stronger public education for students and festival communities

Eddy also invites listeners in Wilmington, Delaware and nearby regions to connect if they need a psychiatric mental health nurse practitioner for psychedelic related research. She hopes to bring her lived experience and clinical skills into the emerging field as psilocybin and other treatments move toward approval.

Frequently Asked Questions

Who is Evelyn Eddy Shoop PMHNP-BC?
She is a psychiatric mental health nurse practitioner trained at the University of Pennsylvania, a former Division I athlete, and a psilocybin trial participant who now advocates for more humane and data informed psychedelic care.

What did Eddy learn from her psilocybin clinical trial experience?
She learned that the hardest sessions can lead to deep change when integration support is strong and when there is time to unpack insights, rather than rushing to rate symptoms on a scale.

Why does she care so much about qualitative data in psychedelic research?
Eddy believes that numbers cannot capture the full human impact of psychedelic therapy. Stories show how people actually live with their disorders and integrate change, which is vital for ethical practice and policy.

How does she view psychedelic harms and psychosis risk?
She acknowledges real risks, especially for people with certain histories, but also notes that some psychotic experiences are not distressing. She calls for more precise language, better containers, and honest harm reduction education.

What role does a psychiatric nurse practitioner like Evelyn play in psychedelic care?
Practitioners like Evelyn can assess risk, prescribe within legal frameworks, provide preparation and integration, and help bridge the gap between traditional psychiatry and emerging psychedelic therapies.

Psychedelic care is evolving fast, and this episode shows why voices like Evelyn Eddy Shoop PMHNP-BC are essential in the current psychedelic resurgence. Her blend of lived experience, clinical training, and critical thinking points toward a future where data and story, safety and possibility, can finally grow together.